Prostate Cancer in China
Overview
Prostate cancer is the most common male cancer and usually slow-growing. Modern risk stratification matches each patient to the right option — from active surveillance for low-risk disease to robotic surgery or precision radiotherapy for aggressive tumors.
Chinese urology centers run high-volume robotic prostatectomy programs with nerve-sparing techniques that preserve urinary control and erectile function.
Symptoms & Signs
Urinary frequency, weak stream and nocturia — usually from coexisting benign enlargement rather than the cancer itself
Early cancer is typically silent and detected by PSA blood testing
Blood in urine or semen in locally advanced disease
Bone pain, particularly in the lower back and hips, when disease has spread
Unexplained weight loss and fatigue in advanced stages
Many screen-detected cancers would never cause symptoms if left untreated, hence the surveillance option
Diagnosis
PSA blood testing, often with free-to-total PSA ratio
Multiparametric MRI (mpMRI) of the prostate identifying suspicious lesions
MRI-ultrasound fusion targeted biopsy of suspicious areas
PSMA PET-CT for precise staging of intermediate and high-risk disease
Gleason/ISUP grading from biopsy determining aggressiveness
Genomic testing of biopsy tissue refining risk estimates
Treatment Options
Active surveillance with regular PSA, MRI and biopsy for low-risk disease
Robotic radical prostatectomy with nerve-sparing technique for localized intermediate and high-risk cancer
External-beam radiotherapy (IMRT) with or without brachytherapy boost
SBRT delivering curative doses in five sessions
Androgen-deprivation therapy with novel hormonal agents for advanced disease
Chemotherapy and targeted radiotherapy (e.g. radium-class) for metastatic stages
Advanced Technologies & Novel Drug
da Vinci robotic surgery with intraoperative nerve monitoring
Fusion biopsy platforms fusing MRI targets with live ultrasound
PSMA PET molecular imaging redefining staging accuracy
LDR brachytherapy and focal-therapy options for selected tumors
Novel androgen-receptor inhibitors and PARP inhibitors for advanced disease
Hospital & Specialist
- Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS) — Beijing
- Tianjin Medical University General Hospital — Tianjin
- Peking University First Hospital (PKUHSC) — Beijing
- Sun Yat-sen University Cancer Center (SYSUCC) — Guangzhou
- Li Han Zhong — Urology
- Kong Liang — Urology
- Wang Xiang — Urology
- Lu Yi Qun — Urology